{"protocolSection":{"identificationModule":{"nctId":"NCT06471569","orgStudyIdInfo":{"id":"Pro00115833"},"secondaryIdInfos":[{"id":"5P30AG028716-18","type":"NIH","link":"https://reporter.nih.gov/quickSearch/5P30AG028716-18"}],"organization":{"fullName":"Duke University","class":"OTHER"},"briefTitle":"Role of Aging and Individual Variation in Exercise Training Responsiveness","officialTitle":"The Role of Aging and Individual Variation in Exercise Training Responsiveness","acronym":"STRRIDE IV"},"statusModule":{"statusVerifiedDate":"2024-06","overallStatus":"NOT_YET_RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2024-09","type":"ESTIMATED"},"primaryCompletionDateStruct":{"date":"2025-09","type":"ESTIMATED"},"completionDateStruct":{"date":"2025-09","type":"ESTIMATED"},"studyFirstSubmitDate":"2024-06-10","studyFirstSubmitQcDate":"2024-06-21","studyFirstPostDateStruct":{"date":"2024-06-24","type":"ACTUAL"},"lastUpdateSubmitDate":"2024-06-21","lastUpdatePostDateStruct":{"date":"2024-06-24","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Duke University","class":"OTHER"},"collaborators":[{"name":"National Institutes of Health (NIH)","class":"NIH"},{"name":"National Institute on Aging (NIA)","class":"NIH"}]},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"The primary purpose of this study is to assess the effects of aging on markers of physical reserve and exercise-induced adaptations in resilience in older adults who completed a structured exercise program within the last 15 years (Parent trial: STRRIDE-PD; NCT00962962). This feasibility pilot study will enroll up to 8 participants to complete a 6-month aerobic exercise intervention."},"conditionsModule":{"conditions":["Prediabetic State","Cardiovascular Diseases","Insulin Resistance","Obesity"],"keywords":["Exercise","Cardiorespiratory Fitness","Functional Capacity","Cardiometabolic Risk","Physical Reserve","Physical Resilience"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["NA"],"designInfo":{"allocation":"NON_RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"PREVENTION","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":8,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Low Amount/Moderate Intensity (Low/Mod)","type":"EXPERIMENTAL","description":"Six months of low amount/moderate intensity aerobic exercise","interventionNames":["Behavioral: Low/Mod"]},{"label":"High Amount/Moderate Intensity (High/Mod)","type":"EXPERIMENTAL","description":"Six months of high amount/moderate intensity aerobic exercise","interventionNames":["Behavioral: High/Mod"]},{"label":"High Amount/Vigorous Intensity (High/Vig)","type":"EXPERIMENTAL","description":"Six months of high amount/vigorous intensity aerobic exercise","interventionNames":["Behavioral: High/Vig"]}],"interventions":[{"type":"BEHAVIORAL","name":"Low/Mod","description":"Aerobic exercise at 50% peak oxygen consumption expending approximately 1000 kilocalories per week equaling approximately 10 miles per week","armGroupLabels":["Low Amount/Moderate Intensity (Low/Mod)"]},{"type":"BEHAVIORAL","name":"High/Mod","description":"Aerobic exercise at 50% peak oxygen consumption expending approximately 1600 kilocalories per week equaling approximately 16 miles per week","armGroupLabels":["High Amount/Moderate Intensity (High/Mod)"]},{"type":"BEHAVIORAL","name":"High/Vig","description":"Aerobic exercise at 75% peak oxygen consumption expending approximately 1600 kilocalories per week equaling approximately 16 miles per week","armGroupLabels":["High Amount/Vigorous Intensity (High/Vig)"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Insulin Sensitivity","description":"Insulin sensitivity will be measured with a 2-hour oral glucose tolerance test","timeFrame":"Baseline, early-intervention (~6 weeks), and post-intervention (~24 weeks)"},{"measure":"Cardiorespiratory Fitness","description":"Cardiorespiratory fitness will be measured with a maximal cardiopulmonary exercise test","timeFrame":"Baseline, early-intervention (~6 weeks), and post-intervention (~24 weeks)"}],"secondaryOutcomes":[{"measure":"Perceived global physical Health","description":"Self-reported health outcomes (including global physical health) will be captured using the Patient-Reported Outcomes Measurement Information System (PROMIS).","timeFrame":"Baseline, early-intervention (~6 weeks), and post-intervention (~24 weeks)"},{"measure":"Perceived global mental Health","description":"Self-reported health outcomes (including global mental health) will be captured using the Patient-Reported Outcomes Measurement Information System (PROMIS).","timeFrame":"Baseline, early-intervention (~6 weeks), and post-intervention (~24 weeks)"},{"measure":"Health-Related Quality of Life","description":"Self-reported quality of life outcomes will be captured using the SF-36 Health Survey. The survey is scored into eight domains: physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health.","timeFrame":"Baseline, early-intervention (~6 weeks), and post-intervention (~24 weeks)"},{"measure":"Metabolic Syndrome Score","description":"Continuous metabolic syndrome scores are calculated using differences between Adult Treatment Panel III guideline values and participant values for mean arterial blood pressure, minimal waist circumference, fasting HDL-C, triglycerides, and glucose with normalization to the cohort standard deviations.","timeFrame":"Baseline, early-intervention (~6 weeks), and post-intervention (~24 weeks)"},{"measure":"Body Composition","description":"Body composition will be assessed as percent fat mass and percent fat-free mass.","timeFrame":"Baseline and post-intervention (~24 weeks)"},{"measure":"Physical Function","description":"The Short Physical Performance Battery will objectively assess lower extremity function related to gait, balance, and strength in older adults. The 6-minute walk test will provide a measure of functional status or fitness.","timeFrame":"Baseline, early-intervention (~6 weeks), and post-intervention (~24 weeks)"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Individuals who completed participation in the STRRIDE-PD trial (NCT00962962)\n* Stable dose (â‰¥1 month) of any cardiometabolic medications\n\nExclusion Criteria:\n\n* Poor vein access\n* Current use of tobacco or any nicotine products, including e-cigarettes\n* Insulin-dependent diabetes\n* Systemic inflammatory or connective tissue disease, chronic infectious disease, chronic pulmonary disease or symptomatic cardiovascular disease with positive functional study by ECG or imaging\n* Current, actively treated malignancy\n* Presence of cardiac arrhythmias that prohibit safe exercise testing or any other absolute or relative contraindication to exercise based on current guidelines from the American College of Sports Medicine\n* Unable to safely participate in an exercise program per study protocol per PI discretion","healthyVolunteers":false,"sex":"ALL","minimumAge":"60 Years","maximumAge":"90 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"Johanna L Johnson, MS","role":"CONTACT","phone":"9196606766","email":"johanna.johnson@duke.edu"},{"name":"Leanna M Ross, PhD","role":"CONTACT","phone":"9196606688","email":"leanna.ross@duke.edu"}],"overallOfficials":[{"name":"Leanna M Ross, PhD","affiliation":"Duke University","role":"PRINCIPAL_INVESTIGATOR"}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-07-01"},"conditionBrowseModule":{"meshes":[{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000007333","term":"Insulin Resistance"},{"id":"D000011236","term":"Prediabetic State"}],"ancestors":[{"id":"D000006946","term":"Hyperinsulinism"},{"id":"D000044882","term":"Glucose Metabolism Disorders"},{"id":"D000008659","term":"Metabolic Diseases"},{"id":"D000003920","term":"Diabetes Mellitus"},{"id":"D000004700","term":"Endocrine System Diseases"}],"browseLeaves":[{"id":"M12701","name":"Obesity","relevance":"LOW"},{"id":"M14117","name":"Prediabetic State","asFound":"Prediabetic State","relevance":"HIGH"},{"id":"M10370","name":"Insulin Resistance","asFound":"Insulin Resistance","relevance":"HIGH"},{"id":"M9997","name":"Hyperinsulinism","relevance":"LOW"},{"id":"M11639","name":"Metabolic Diseases","relevance":"LOW"},{"id":"M25403","name":"Glucose Metabolism Disorders","relevance":"LOW"},{"id":"M7115","name":"Diabetes Mellitus","relevance":"LOW"},{"id":"M7862","name":"Endocrine System Diseases","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC18","name":"Nutritional and Metabolic Diseases"},{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC19","name":"Gland and Hormone Related Diseases"}]}},"hasResults":false}